May 28, 2013 at 4:51 AM 
DCPrime’s Phase I/IIa Trial with Dendritic Cancer Vaccine in Acute Myeloid Leukemia Meets All Clinical Endpoints
Cancer vaccine company DCPrime today announced the successful completion of its Phase I/IIa study in acute myeloid leukemia (AML). The study shows clear evidence of a positive, vaccination induced immune response. Remarkably, several patients showed prolonged survival compared to historic expectations.

Aug 08, 2012 at 7:06 AM
ImmunoCellular Therapeutics’ Data From Phase I Trial of ICT-107 Accepted for Publication in Prestigious Medical Journal, Cancer Immunology, Immunotherapy
Phase I study to evaluate the safety and immune responses to ICT-107, 21 patients were enrolled, including 17 newly diagnosed and three recurrent GBM patients and one with brainstem glioma. At a median follow-up of 40.1 months, six of the newly diagnosed patients showed no evidence of tumor recurrence.

January 24, 2012 at 1:18 AM 
ImmunoCellular initiates enrollment in ICT-107 Phase II trial for GBM in 23 centers…  The trial is expected to enroll approximately 160-200 patients to treat 102 patients with HLA-A1/A2 immunological subtypes.

November 25, 2011 at 11:33 AM
Immunicum, which is developing cancer vaccines, has received approval from the Swedish Medical Products Agency to start its first clinical trial. The study will be conducted on kidney cancer patients at the University Hospital in Uppsala….. Immunicum’s vaccine is based on using dendritic cells from healthy individuals and can thus be mass-produced, leading to significant commercial advantages.

Business Wire Thu, 09 June 2011 08:30 AM PDT
ICT-107 is the Company’s dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM). …

Business Wire Wed, 08 June 2011 07:30 PM PDT
Dr. Anthony Maida, a well known senior executive in the field of cancer immune therapies … of the dendritic cells and their potential for fighting cancer. …

Business Wire Wed, 18 May 2011 07:03 AM PDT
Northwest Biotherapeutics (OTCBB:NWBO) announced today that it is partnering with Fraunhofer for production of DCVax®-L for brain cancer, for clinical trials and compassionate use cases in Europe. Fraunhofer is a highly respected leader in many areas of technology, including cell and immune therapies.

Business Wire Wed, 18 May 2011 07:03 AM PDT
Northwest Biotherapeutics (OTCBB:NWBO) announced today that it is partnering with Fraunhofer for production of DCVax®-L for brain cancer, for clinical trials and compassionate use cases in Europe. Fraunhofer is a highly respected leader in many areas of technology, including cell and immune therapies.

Enhanced Online News Tue, 22 Jun 2004 5:50 AM PDT
DURHAM, NC & TOKYO–(BUSINESS WIRE)–June 22, 2004–Merix Bioscience, a company pioneering therapeutic immunotherapy vaccines, and Kirin Brewery’s Pharmaceutical Division, which is developing therapeutic products for renal disease, cancer and immunological disorders, today announced the signing of a collaboration agreement for developing therapies using dendritic cells.

News Observer Tue, 22 Jun 2004 1:29 AM PDT
Merix Bioscience in Durham is partnering with a Japanese company to develop and market its personalized cancer vaccines in a deal that will bring in millions of dollars in additional operating cash. Kirin and Geron Announce Settlement of Lawsuit

StockHouse U.S. Mon, 21 Jun 2004 10:28 PM PDT
MENLO PARK, Calif., Kirin Brewery Co., Ltd. and Geron Corporation (Nasdaq:GERN) announced today that they have amicably resolved the litigation between them.

Bio-IT World Tue, 22 Jun 2004 8:32 AM PDT
(06/22/04) Cellomics has inked a non-exclusive, worldwide patent license agreement for its core High-Content Screening (HCS) patent portfolio with GE Healthcare (the merged entity of Amersham and GE Medical Systems).